sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group's Securities Disclosure on Avadel Pharmaceuticals
The Vanguard Group, Inc. has disclosed its position in Avadel Pharmaceuticals plc under Form 8.3, as required by the Irish Takeover Panel Act of 1997. This disclosure covers interests in relevant securities amounting to 1% or more. The document, dated January 2, 2026, outlines Vanguard's current holding in Avadel, which consists of 5,861,488 US$0.01 ordinary shares, representing a 6.02% interest.
In recent trading activity, Vanguard purchased 1,560 shares at $21.52 each and sold 4,853 shares at the same price. Vanguard currently holds no cash-settled derivatives or stock-settled derivatives related to Avadel. The form indicates no existing indemnity or dealing arrangements nor any agreements related to options or derivatives concerning Avadel's securities.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.